Emmaus Life Sciences

Emmaus Life Sciences(EMMA)

TORRANCE, CA
Biotechnology
WebsiteLinkedInCareers Page

Focus: Oral amino acid treatment

Emmaus Life Sciences is a life sciences company focused on Oral amino acid treatment.

Rare DiseasesMetabolic Diseases
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (1)

1 discontinued product not shown

ENDARI
glutamine
Peak
ORAL · FOR SOLUTION
L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive events associated with SCD. The pyridine nucleotides, NAD and its reduced form NADH, play roles in regulating and preventing oxidative damage in RBCs. L-glutamine may improve the NAD redox potential in sickle RBCs through increasing the availability of reduced glutathione.
acute complications of sickle cell disease in adultolder
2017
30

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 2 approved products
Top TAs: Metabolic Diseases, Rare Diseases
SEC Filings: 2 available
Portfolio Health
Peak1 (50%)
LOE Approaching1 (50%)
2 total products
Therapeutic Area Focus
Rare Diseases
1 marketed
Marketed
Pipeline

Financials (FY2024)

Revenue
$30M61%
R&D Spend
$1M(4%)31%
Net Income
-$4M
Cash
$3M
Source: SEC 10-K Filing